CGI121 Antibody

What is CGI121 and why is it significant in research?

CGI121 is a non-catalytic subunit of the KEOPS (Kinase, Endopeptidase, and Other Proteins of Small size) complex, which is evolutionarily conserved across eukaryotes and archaea. The protein plays critical roles in tRNA modification, stress responses, and cellular homeostasis, making it a significant target for research in molecular biology and genetics. One of the most important functions of CGI121 is binding the 3′ CCA tail of tRNAs, which facilitates the transfer of the threonylcarbamoyl group to adenosine at position 37 (t6A37). This modification is crucial for translational fidelity and proper protein synthesis. CGI121's involvement in fundamental cellular processes such as stress response pathways also makes it relevant for research in pathology, particularly in understanding fungal pathogen virulence.

The significance of CGI121 extends beyond its direct functions, as it represents an important component in a complex molecular machine that has been conserved throughout evolution. Recent structural studies have revealed that CGI121 forms an extended tRNA-binding surface together with other KEOPS subunits, highlighting its essential role in tRNA substrate interactions and subsequent modification . Additionally, CGI121 has been shown to possess dsDNA-binding activity that relies on its tRNA 3′ CCA tail binding module, suggesting multifunctional capabilities that warrant further investigation .

What are the specific applications of CGI121 antibodies in research?

CGI121 antibodies find application in multiple research contexts, primarily in investigating tRNA modification mechanisms and KEOPS complex assembly. The monoclonal Anti-CGI-121 antibody (clone 3F6) produced in mouse is commonly used for detecting human CGI121 in various experimental settings. Western blotting represents one of the primary applications, with recommended concentrations of 1–5 μg/mL for optimal detection. Researchers also employ these antibodies in indirect ELISA assays to quantify CGI121 expression levels across different experimental conditions.

In structural biology research, CGI121 antibodies are instrumental for mapping interactions between CGI121 and tRNA or other KEOPS subunits via co-immunoprecipitation techniques. These approaches help elucidate the molecular architecture of the KEOPS complex and its interaction with substrate molecules. Furthermore, CGI121 antibodies have proven valuable in pathogen research, particularly for assessing virulence pathways in Cryptococcus neoformans and other fungal pathogens where CGI121 contributes to stress resistance and virulence factor production. The specificity of these antibodies for different species variants of CGI121 enables comparative studies across evolutionary lineages, contributing to our understanding of the conserved functions of this protein.

What is the structure and composition of the CGI121 protein?

The CGI121 protein is part of the four-core subunit KEOPS complex, which also includes Pcc1, Kae1, and Bud32. Structural analyses have revealed that CGI121 contains distinctive helical elements that form a discrete surface primarily composed of helices-α1, -α3, and -α4, which are especially sensitive to tRNA binding . This helical arrangement creates a binding pocket that accommodates the 3′ CCA tail of tRNAs, an essential element common to mature tRNAs that serves as the accepting site for aminoacylation .

X-ray crystallography studies of Methanocaldococcus jannaschii CGI121 (mjCGI121) have provided detailed structural insights into the protein's conformation and binding interfaces. Size exclusion chromatography experiments have shown that wild-type mjCGI121 (MW = 17 kDa) can elute as two distinct peaks with estimated sizes of 20 and 40 kDa, suggesting potential dimerization or complex formation with other molecules . The protein's structure enables it to recognize specific elements of tRNA molecules, particularly the CCA tail, which is essential for its function in tRNA modification pathways.

NMR studies using 15N-labeled mjCGI121 have further confirmed direct binding interactions with tRNA, evidenced by complete loss of resonance peaks in HSQC spectra upon tRNA addition . These structural characteristics make CGI121 a fascinating subject for structure-function relationship studies and highlight the importance of specific amino acid residues in mediating its interactions with nucleic acids.

How does CGI121 interact with other components of the KEOPS complex?

CGI121 interacts with other KEOPS subunits to form an extended tRNA-binding surface that collectively mediates interaction with tRNA substrates . Within this complex, CGI121 specifically serves as the primary tRNA recruitment module through its interaction with the 3′ CCA tail of tRNAs . The protein directly associates with Bud32, another KEOPS subunit, forming a mjCGI121–mjBud32 complex that exhibits enhanced tRNA binding capabilities compared to CGI121 alone .

Experimental evidence indicates that when CGI121 is complexed with other KEOPS subunits, its tRNA binding characteristics are modified. For instance, tRNA is approximately 17-fold more potent at displacing a fluorescently labeled CCA probe from CGI121 than an unlabeled CCA-oligo when CGI121 is in complex with other subunits, suggesting that features beyond the CCA tail contribute to tRNA binding in the context of the complete KEOPS complex . This observation highlights the cooperative nature of substrate recognition within multiprotein complexes.

Integration of the CGI121–tRNA crystal structure into a composite model of KEOPS has revealed that all four KEOPS subunits participate in positioning the A37 modification site of tRNA into the catalytic cleft of Kae1 . This collaborative arrangement explains why all KEOPS subunits are essential for efficient t6A modification activity, as disruption of any component compromises the proper positioning of the substrate for catalysis.

What are the optimal conditions for using CGI121 antibodies in Western blotting?

The monoclonal Anti-CGI-121 antibody (clone 3F6) produced in mouse is recommended for Western blotting applications at concentrations ranging from 1 to 5 μg/mL for optimal detection of human CGI121. When preparing samples for Western blotting, it is advisable to use standard protein extraction protocols suitable for nuclear and cytoplasmic proteins, as CGI121 can be present in both cellular compartments due to its involvement in tRNA modification. Samples should be denatured in standard SDS-PAGE loading buffer containing reducing agents and heated at 95°C for 5 minutes before loading onto polyacrylamide gels.

For protein transfer, both wet and semi-dry transfer methods are compatible with CGI121 detection, though wet transfer may yield superior results for high molecular weight complexes containing CGI121. Blocking should be performed using 5% non-fat dry milk or bovine serum albumin (BSA) in Tris-buffered saline with 0.1% Tween-20 (TBST) for 1 hour at room temperature. Primary antibody incubation should be conducted overnight at 4°C with gentle agitation, followed by thorough washing with TBST and appropriate secondary antibody incubation.

For validation purposes, researchers should include positive controls such as HEK293T cell lysates, which express detectable levels of endogenous CGI121. Negative controls might include samples from CGI121 knockout cell lines or samples treated with siRNA targeting CGI121, as was demonstrated in experiments with WM-266-4 melanoma cells in which siRNA-mediated depletion of TBC1D7 (another protein studied in the search results) resulted in altered protein expression patterns . These controls help establish the specificity of the antibody and validate experimental findings.

How can researchers effectively use CGI121 antibodies in co-immunoprecipitation experiments?

For effective co-immunoprecipitation (co-IP) experiments using CGI121 antibodies, researchers should begin with careful cell lysis using non-denaturing buffers that preserve protein-protein interactions. A suitable lysis buffer might contain 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40 or 0.5% Triton X-100, and protease inhibitor cocktail. Gentle lysis conditions are particularly important when studying CGI121's interactions with other KEOPS complex subunits or tRNA molecules.

Pre-clearing of cell lysates with protein A/G beads for 1 hour at 4°C is recommended to reduce non-specific binding. For the immunoprecipitation step, 2-5 μg of CGI121 antibody should be added to 500-1000 μg of pre-cleared lysate and incubated overnight at 4°C with gentle rotation. Protein A/G beads are then added and incubated for an additional 2-4 hours before washing extensively with lysis buffer to remove non-specifically bound proteins.

When investigating CGI121's interactions with RNA molecules, such as tRNAs, researchers should consider using RNase inhibitors in their buffers and potentially performing crosslinking to stabilize transient RNA-protein interactions. This approach is supported by studies showing that mjCGI121 purified from Escherichia coli co-purifies with RNA species resembling tRNA (~24 kDa/70–90 bps) . For detecting tRNA in co-IP samples, researchers can employ northern blotting or RT-qPCR methods targeting specific tRNA species of interest.

To validate the specificity of co-IP results, appropriate controls should be included, such as isotype control antibodies and samples from cells expressing mutant versions of CGI121. For instance, mutations disrupting the CCA-binding interface (e.g., Met60Glu, Ile72Glu, or Ile72Lys in mjCGI121) significantly reduce tRNA binding and could serve as important negative controls .

What methods can be used to study CGI121's interaction with tRNA molecules?

Several complementary methods can be employed to study CGI121's interaction with tRNA molecules. Nuclear Magnetic Resonance (NMR) spectroscopy using 15N-labeled CGI121 protein has proven effective in confirming direct binding interactions with tRNA, as evidenced by changes in resonance peaks in HSQC spectra upon tRNA addition . This approach allows researchers to identify specific residues involved in the interaction by monitoring chemical shift perturbations.

X-ray crystallography represents another powerful approach for elucidating the structural basis of CGI121-tRNA interactions. Crystal structures of CGI121 in complex with tRNA or CCA oligonucleotides have revealed the precise binding mode, showing that CGI121 binds tRNA primarily via the 3′ CCA tail . Researchers planning crystallography experiments should focus on optimizing crystallization conditions for these complexes, possibly using synthetic RNA oligonucleotides corresponding to the CCA tail as a starting point.

Fluorescence-based binding assays offer a quantitative approach to measuring CGI121-tRNA interactions. Competitive displacement assays using fluorescently labeled CCA oligonucleotides (e.g., 647-CCA) have successfully demonstrated that tRNA can displace these probes from CGI121, while tRNA lacking the CCA tail (tRNA ΔCCA) cannot . These assays can be adapted to study the effects of mutations in CGI121 or modifications to the tRNA structure on binding affinity.

In vivo approaches, such as CLIP-seq (crosslinking immunoprecipitation followed by sequencing), can be employed to identify the repertoire of tRNAs bound by CGI121 in cellular contexts. This method involves UV crosslinking to stabilize RNA-protein interactions, followed by immunoprecipitation with CGI121 antibodies and sequencing of the associated RNAs, providing insights into the substrate specificity of CGI121 under physiological conditions.

How can CGI121 antibodies be used to investigate the role of CGI121 in disease models?

CGI121 antibodies can be instrumental in investigating the role of this protein in various disease models, particularly in cancer and infectious diseases. In melanoma research, quantitative proteomic approaches similar to those used for TBC1D7 could be employed to assess CGI121 expression levels across primary and metastatic cell lines . Western blotting using CGI121 antibodies at appropriate dilutions (1-5 μg/mL) can quantify expression differences, while immunohistochemistry on tissue microarrays can evaluate expression patterns across patient samples at different disease stages.

For fungal pathogen research, CGI121 antibodies can help assess the relationship between CGI121 expression and virulence factor production. In Cryptococcus neoformans, where CGI121 is essential for virulence factor production such as melanin and capsule formation, immunoblotting of wild-type versus CGI121-deficient strains can quantify associated proteins. Researchers should employ appropriate species-specific CGI121 antibodies or verify cross-reactivity when working with non-human systems.

In infectious disease models, combining CGI121 antibody-based detection with functional assays can reveal mechanistic insights. For instance, researchers could correlate CGI121 expression levels with t6A modification efficiency in pathogen-infected cells using LC-MS/MS to quantify modified nucleosides. This approach would be similar to the LC-PRM methods described for epitranscriptomic studies, where a mixture of stable isotope-labeled peptides was used as internal standards .

When designing such studies, researchers should carefully consider appropriate controls. For genetic manipulation experiments (knockdown, knockout, or overexpression), validation of CGI121 protein levels using the antibodies is essential to confirm the effectiveness of the intervention. Additionally, rescue experiments reintroducing wild-type or mutant CGI121 can provide compelling evidence for specific functional roles, as demonstrated in studies where CGI121 mutations disrupting tRNA binding also perturbed the activity of the KEOPS complex .

What approaches can be used to investigate the role of CGI121 in tRNA modification pathways?

Investigating CGI121's role in tRNA modification pathways requires a multifaceted approach combining biochemical, structural, and genetic methods. In vitro tRNA modification assays represent a direct approach to assess the impact of CGI121 on t6A modification activity. Researchers can reconstitute the KEOPS complex with wild-type or mutant CGI121 proteins and measure t6A formation using radiolabeled substrates or LC-MS/MS detection of modified nucleosides . These assays have demonstrated that disruption of the CGI121–CCA tail interface severely inhibits KEOPS t6A activity, with modifications such as mjCGI121 Met60Glu, mjCGI121 Ile72Glu, or mjCGI121 Ile72Lys abolishing detectable tRNA modification .

Structural approaches using cryo-electron microscopy can capture the complete KEOPS complex in action, providing insights into how CGI121 cooperates with other subunits to position tRNA for modification. These studies would extend existing findings that all KEOPS subunits form an extended tRNA-binding surface essential for substrate interaction and modification . When designing such experiments, researchers should consider using stalled modification intermediates or non-hydrolyzable ATP analogs to capture relevant conformational states.

Genetic approaches using CRISPR-Cas9 to generate CGI121 knockout or knock-in mutant cell lines can reveal the physiological consequences of CGI121 dysfunction. Phenotypic analyses of these cells should focus on translation fidelity (using reporter constructs sensitive to codon misreading), growth under stress conditions, and global protein synthesis rates. These cellular phenotypes can then be correlated with changes in t6A levels across the transcriptome, as measured by techniques such as tRNA-seq combined with mass spectrometry.

For comprehensive characterization of CGI121's role, researchers should also investigate potential regulatory mechanisms controlling CGI121 function. This might include identifying post-translational modifications using immunoprecipitation with CGI121 antibodies followed by mass spectrometry, or examining whether CGI121 activity is regulated by cellular conditions such as nutrient availability or stress, which are known to impact tRNA modification pathways.

What are the considerations for using CGI121 antibodies in studying species-specific differences in KEOPS complex function?

When using CGI121 antibodies to study species-specific differences in KEOPS complex function, researchers must first verify antibody cross-reactivity with CGI121 orthologs from different species. While the monoclonal Anti-CGI-121 antibody (clone 3F6) is primarily designed for human CGI121 detection, sequence alignment and epitope mapping can help predict cross-reactivity with orthologs from model organisms. In cases where cross-reactivity is limited, researchers may need to develop species-specific antibodies using synthetic peptides derived from unique regions of the target orthologs.

Experimental designs for cross-species comparisons should include appropriate controls specific to each organism. For instance, when studying CGI121 in fungal pathogens like Cryptococcus neoformans, researchers should validate antibody specificity using extracts from wild-type and CGI121-deficient strains. Additionally, when comparing CGI121 function across species with different tRNA populations, researchers should consider how variations in tRNA structure and modification status might affect CGI121 interactions.

Immunoprecipitation experiments aimed at isolating KEOPS complexes from different species may require optimization of buffer conditions to account for differences in complex stability and associated proteins. When combined with mass spectrometry, such approaches can reveal species-specific interaction partners of CGI121 that might contribute to functional differences in tRNA modification pathways or other cellular processes involving the KEOPS complex.

What are common issues with CGI121 antibody specificity and how can they be addressed?

Common specificity issues with CGI121 antibodies include cross-reactivity with structurally similar proteins, high background in immunoassays, and batch-to-batch variability in antibody performance. To address these challenges, researchers should first validate each new lot of CGI121 antibody using positive controls (cells known to express CGI121) and negative controls (CGI121 knockout cells or siRNA-treated samples). This validation should be performed for each experimental application, as an antibody that works well for Western blotting may not perform optimally in immunoprecipitation or immunofluorescence.

Cross-reactivity can be assessed through Western blotting of samples from CGI121 knockout cells or through peptide competition assays where the antibody is pre-incubated with the immunizing peptide before application to the sample. A significant reduction in signal in the presence of competing peptide indicates specificity for the target epitope. For the monoclonal Anti-CGI-121 antibody (clone 3F6), which uses a synthetic peptide as immunogen, researchers can design peptide competition experiments using this sequence or fragments thereof.

High background in immunostaining applications can be addressed through optimization of blocking conditions (testing different blocking agents such as BSA, normal serum, or commercial blocking solutions) and antibody dilutions. For Western blotting, increasing the stringency of wash steps and optimizing the concentration of detergent in wash buffers can help reduce non-specific binding. Additionally, using highly purified antibody preparations or considering alternative clones targeting different epitopes may resolve specificity issues.

For particularly challenging applications requiring maximal specificity, researchers might consider using tag-based approaches where CGI121 is expressed with an epitope tag (e.g., FLAG, HA, or V5) and detected using well-characterized anti-tag antibodies. This approach was successfully employed in studies where FLAG-TBC1D7 was overexpressed in WM-115 cells to investigate its function , and similar strategies could be applied to CGI121 research.

How can researchers validate the functional implications of CGI121 interactions observed in antibody-based experiments?

Validating functional implications of CGI121 interactions requires complementary approaches that extend beyond antibody-based detection. Genetic manipulation represents a powerful validation strategy, where researchers can disrupt the CGI121 gene using CRISPR-Cas9 or reduce its expression via RNA interference, followed by assessment of phenotypic consequences. For instance, studies have shown that siRNA-mediated knockdown of TBC1D7 in WM-266-4 melanoma cells affects cell invasion capabilities , and similar approaches could be applied to CGI121 research.

Mutational analysis targeting specific residues involved in protein-protein or protein-RNA interactions provides another validation approach. Based on structural data showing that mutations such as Met60Glu, Ile72Glu, or Ile72Lys in mjCGI121 disrupt tRNA binding , researchers can introduce equivalent mutations in the species of interest and assess functional outcomes. These mutations should abolish specific interactions while minimizing disruption to protein folding and stability.

Functional readouts specific to CGI121's role in tRNA modification should be employed to connect observed interactions to biological consequences. These might include quantification of t6A levels in tRNAs using mass spectrometry, assessment of translational fidelity using reporter systems sensitive to codon misreading, or measurement of growth phenotypes under conditions where accurate translation is particularly important, such as during exposure to protein synthesis inhibitors or oxidative stress.

For interactions identified through co-immunoprecipitation experiments, reciprocal validation using antibodies against the interaction partner can strengthen confidence in the results. Additionally, proximity ligation assays or fluorescence resonance energy transfer (FRET) experiments can provide evidence for interactions in intact cells, complementing in vitro binding studies and immunoprecipitation results. These approaches help distinguish physiologically relevant interactions from those that might occur artifactually during cell lysis or extract preparation.

What are the best practices for quantifying CGI121 expression levels across different experimental conditions?

Accurate quantification of CGI121 expression levels requires careful attention to experimental design and data analysis. Western blotting combined with densitometry remains a common approach, but researchers should adhere to best practices, including appropriate loading controls (housekeeping proteins like GAPDH or β-actin), linear range determination for both primary antibodies, and multiple biological replicates for statistical analysis. When comparing expression across different cell types or tissues, researchers should consider using multiple reference proteins as loading controls to account for potential variation in "housekeeping" gene expression.

For more precise quantification, quantitative immunoassays such as ELISA can be developed using the monoclonal Anti-CGI-121 antibody (clone 3F6). These assays should include a standard curve using recombinant CGI121 protein of known concentration and should be validated for linearity, specificity, and reproducibility across the expected range of CGI121 expression in experimental samples.

Mass spectrometry-based proteomics offers the most comprehensive and precise approach for CGI121 quantification, particularly when employing targeted methods like liquid chromatography–parallel-reaction monitoring (LC-PRM) similar to those described for epitranscriptomic proteins . For absolute quantification, a mixture of stable isotope-labeled (SIL) peptides representing CGI121 can serve as internal standards, allowing for accurate determination of protein levels across different samples.

How might emerging technologies enhance the study of CGI121 using antibody-based approaches?

Emerging technologies are poised to revolutionize antibody-based studies of CGI121, offering unprecedented insights into its function and interactions. Single-cell proteomics techniques could enable researchers to examine CGI121 expression heterogeneity within populations of cells, potentially revealing subpopulations with distinct KEOPS complex activities or regulatory states. This approach would be particularly valuable for studying CGI121 in complex tissues or during developmental processes where cellular heterogeneity is pronounced.

Advanced imaging technologies such as super-resolution microscopy combined with CGI121 antibodies could reveal the spatial organization of CGI121 and the KEOPS complex within cellular compartments at nanometer resolution. These techniques might uncover previously unrecognized subcellular localizations or dynamic changes in complex assembly in response to cellular signals. For example, researchers could investigate whether CGI121 forms distinct foci associated with specific nuclear domains involved in tRNA processing or modification.

Proximity labeling methods like BioID or APEX, when coupled with CGI121 as the bait protein, could map the protein interaction landscape of CGI121 in living cells with temporal resolution. These approaches would complement traditional co-immunoprecipitation experiments by capturing transient or weak interactions that might be lost during cell lysis and extraction procedures. The resulting interaction networks could reveal unexpected connections between tRNA modification pathways and other cellular processes.

CRISPR-based technologies for precise genome editing, combined with knock-in of fluorescent or affinity tags at the endogenous CGI121 locus, could enable tracking of CGI121 dynamics in live cells without overexpression artifacts. Additionally, developments in cryo-electron tomography might soon allow visualization of KEOPS complexes within their native cellular environment, providing structural insights into how these complexes organize and function within the complex milieu of the cell.

What are potential new applications of CGI121 antibodies in studying the role of tRNA modifications in disease?

CGI121 antibodies hold promise for investigating the emerging connections between tRNA modifications and disease pathogenesis. In cancer research, CGI121 antibodies could be employed in tissue microarray studies to assess expression patterns across tumor types and stages, potentially identifying cancers where KEOPS complex dysregulation contributes to disease progression. This approach would be similar to studies investigating TBC1D7 in melanoma metastasis , but focused on CGI121's role in tRNA modification and translational control.

Neurodegenerative diseases represent another promising area for CGI121 antibody applications, as emerging evidence suggests that defects in tRNA modification and translational fidelity may contribute to protein misfolding and aggregation. Researchers could use CGI121 antibodies to examine protein expression and localization in brain tissues from patients with conditions such as Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis, looking for correlations between CGI121 abnormalities and disease pathology.

In the field of infectious diseases, CGI121 antibodies could help elucidate how pathogens interact with or manipulate host tRNA modification machinery during infection. For instance, researchers might investigate whether viral infections alter CGI121 expression or localization as part of strategies to hijack host translation machinery. Similarly, in bacterial infections like tuberculosis, where tRNA modifications play roles in virulence and antibiotic resistance, CGI121 antibodies could help track changes in the host KEOPS complex in response to infection.

Advances in precision medicine might also benefit from CGI121 antibody applications, particularly in developing diagnostic or prognostic tools based on CGI121 expression or post-translational modification status. If specific patterns of CGI121 alteration are associated with disease subtypes or treatment responses, immunoassays using CGI121 antibodies could be developed into clinical tests. This approach would require extensive validation across patient cohorts but could potentially identify patient subgroups most likely to benefit from therapies targeting translational fidelity or stress response pathways.

How can researchers integrate CGI121 antibody-based studies with other 'omics approaches for systems-level understanding?

Integration of CGI121 antibody-based studies with multi-omics approaches can provide comprehensive insights into the role of tRNA modifications in cellular physiology. Researchers can combine immunoprecipitation using CGI121 antibodies with RNA sequencing (RIP-seq) to identify the full repertoire of tRNAs and potentially other RNAs that interact with CGI121 in different cellular contexts. This data can then be integrated with tRNA modification profiling using mass spectrometry to correlate CGI121 binding with specific modification patterns.

Proteomics approaches such as SILAC (Stable Isotope Labeling by Amino acids in Cell culture) combined with CGI121 perturbation (knockout, knockdown, or overexpression) can reveal the impact of CGI121-mediated tRNA modifications on the global proteome . These experiments might identify specific proteins or pathways whose expression is particularly sensitive to alterations in t6A modification, providing insights into the downstream consequences of CGI121 dysfunction. Researchers should design these experiments with appropriate controls and replicates to enable statistical analysis of differentially expressed proteins.

Metabolomics represents another valuable approach for integration with CGI121 antibody studies, as tRNA modifications can influence translation efficiency and potentially impact metabolic pathways. Researchers might investigate how CGI121 perturbation affects cellular metabolite profiles, particularly focusing on amino acid metabolism and energy production pathways that are closely linked to protein synthesis demands. These studies could reveal unexpected connections between tRNA modification and metabolic regulation.

For systems-level integration, computational approaches combining data from multiple 'omics platforms with network analysis can help construct comprehensive models of CGI121 function. These models can generate testable hypotheses about regulatory mechanisms and functional interactions that may not be apparent from individual experiments. When publishing such integrated analyses, researchers should make raw data and analytical pipelines available to the scientific community to enable further exploration and validation of the findings.